The TOPIX Global Market 250 Index is slightly up, with attention turning to the main board as the increase narrows.

The Tokyo Stock Exchange Growth Market Index was 842.86, up 0.35%, with a volume of 178.08 million shares and sales of 124.5 billion yen. The Tokyo Stock Exchange Growth Market 250 Index was 653.92, up 0.89%, with a volume of 122.33 million shares and sales of 91.7 billion yen. Today's growth market saw slight gains in both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index. The number of rising stocks was 226, the number of falling stocks was 308, and the unchanged stocks were 50. The US stock market on the 3rd was mixed. The Dow average fell $23.85 (-)

Fisco JapanJul 4 03:37 ET

The TOPIX Global Market 250 index rebounded for the first time in four days, led by the main stocks.

Tokyo Stock Exchange Growth Market Index 842.51 +8.29 / Volume 216,130,000 shares / Trading value 132.9 billion yen. Tokyo Stock Exchange Growth Market 250 Index 653.03 +6.99 / Volume 147,600,000 shares / Trading value 83.0 billion yen. Today's growth market saw a rebound for both Tokyo Stock Exchange Growth Market Index and Tokyo Stock Exchange Growth Market 250 Index after a 4-day decline. The number of rising stocks was 327, the number of declining stocks was 225, and the unchanged stocks were 35. The US stock market on the 2nd continued to rise. The Dow Jones Industrial Average was up 162.33 dollars (

Fisco JapanJul 3 03:45 ET

Press release regarding the approval of sales for Abatroxibag maleate tablets by Gyre Therapeutics.

As announced on July 1st, regarding the approval for the sale of the Torobipagmalein Tablet (20mg), our subsidiary Gyre Therapeutics has also made an announcement. Among them, there is a comment from Dr. Han-In, the CEO of Gyre Therapeutics. 'Han Ying, CEO of Gyre Therapeutics, commented, "The National Medical Products Administration has approved Torobipag for commercial sale in China, which represents a significant achievement for Gyre and we look forward to bringing this important therapy to patients who are suffering from thrombocytopenia in China."'

GNI GroupJul 2 11:00 ET

GNI Group Announces New Drug Approval in China

TipRanksJul 1 05:57 ET

The Tokyo Stock Exchange's Gross Index continues to fall, with individual stock picking remaining lackluster for the day.

Tokyo Stock Exchange Growth Market Index 837.95 -13.47 / Volume 213,070,000 shares / Trading value 161.5 billion yen Tokyo Stock Exchange Growth Market 250 Index 649.20 -12.04 / Volume 111,080,000 shares / Trading value 105.3 billion yen In today's growth market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index continued to decline. The number of rising stocks was 191, the number of falling stocks was 357, and the unchanged was 35. On June 28th, the Dow Jones Industrial Average fell by 45.20 dollars in the US market.

Fisco JapanJul 1 03:48 ET

Introduction of Beijing Time broadcasting media.

On June 28th, GYRE Pharmaceuticals, a company based in Beijing, was featured on a broadcast media for developing a groundbreaking drug (F351) to treat liver fibrosis caused by Hepatitis B. The video also introduces the company's factory and manufacturing process. Please click on the link below to watch. GYRE Pharmaceuticals: Develops the first innovative drug to treat liver fibrosis caused by Hepatitis B in the world_Beijing Time (btime.com)

GNI GroupJun 30 11:00 ET